Myriad Genetics Reports Fiscal First-Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Myriad Genetics (MYGN) PT Raised to $47 at Piper Jaffray
November 4, 2015 8:50 AM ESTPiper Jaffray analyst William Quirk reiterated an Overweight rating and boosted his price target on Myriad Genetics (NASDAQ: MYGN) to $47.00 (from $45.00) following Q1 beat.
Quirk commented, "Myriad's 1Q16 revenue increased 9% yoy to $183.5M, above consensus of $177.9M (PJC: $177.6M). Adjusted EPS of $0.41 was above consensus'... More
Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined
November 4, 2015 7:57 AM ESTMizuho Securities analyst Eric Criscuolo bumped his price target on Myriad Genetics (NASDAQ: MYGN) to $42.00 (from $38.00) following results but remains on the sidelines with a Neutral rating.
Criscuolo commented, "We are upping our PT to $42 but remain on the sidelines. MYGN reported... More
Myriad Genetics (MYGN) PT Up to $46 at Leerink Partners After Solid Q1
November 4, 2015 7:21 AM ESTLeerink Partners analyst Dan Leonard lifted his price target on Myriad Genetics (NASDAQ: MYGN) to $46.00 (from $37.00) following solid Q1 results but maintained a Market Perform rating.
Leonard commented, "We are nudging up our FY16 estimates following MYGN's solid September quarter (F1Q),... More
Myriad Genetics (MYGN) Tops Q1 EPS by 6c
November 3, 2015 4:14 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $183.5 million versus the consensus estimate of $177.89 million.
Myriad Genetics sees FY2015 EPS of $1.60-$1.65, versus the consensus of $1.64. Myriad Genetics sees FY2015... More
